Collectively, these findings provide evidence that targeting DNMT1 and HDAC1 enhances the expression of PD-L1, and the concurrent administration of an anti-PD-L1 agent represents a novel approach for the treatment of breast cancer. Here, DNMT1 is linked to breast cancer.